• About
  • Overview
  • Management
    • Dr. Joe Lewis
    • Sally-Anne Watson
  • Supervisory Board
  • Scientific Advisory Board
  • Investors
• Programs
  • Mechanism of Action
  • Technology
  • Products
  • Technology Fact Sheet
• News
  • Latest News
  • Upcoming Events
  • Download Area
• Careers
  • Vacancies
• Contact
  • Contact
• Home
  • Home

Welcome to Elara Pharmaceuticals

ELARA Pharmaceuticals GmbH is a pre-clinical stage biopharmaceutical company founded in 2006 as a spin-out of the European Molecular Biology Laboratory (EMBL) in Heidelberg.

The company focuses on the development of novel treatments for malignant diseases through inhibition of the hypoxia signaling pathway (HIF), which is crucial for tumor survival and growth, and through induction of apoptosis. Since HIF is upstream of validated oncology targets, this approach is expected to yield drugs of superior efficacy to current standards of care.

ELARA at BIO Europe Spring 2012:

Meet ELARA at the BIO Europe Spring in Amsterdam where and learn about EL102, its late preclinical stage hypoxia signaling inhibitor being developed for multiple myeloma.

Publication: ELARA's collaborators at the IDD in San Antonio have published an excellent paper on the mechanism of action of one of our backup molecules in renal cell carcinoma: view paper here